Journal
CANCER LETTERS
Volume 312, Issue 1, Pages 101-108Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.08.006
Keywords
Breast cancer; RU-486; WNT1
Categories
Funding
- Wilhelm Sander-Foundation [2007.005.01, .2007.005.02]
- DFG Research group SKELMET FOR [HO 1875/12-1, 13-1]
Ask authors/readers for more resources
The Wnt signaling pathway is activated in over 50% of women with breast cancer and contributes to tumor progression. Here, we investigated the effects of RU-486 on Wnt signaling in breast cancer cell lines. RU-486 reduced viability of the progesterone receptor-positive MCF-7 and T-47D cells, but had no effect on the triple-negative MDA-MB-231 cells. Furthermore, RU-486 suppressed WNT1 expression of MCF-7 cells by 99%. The addition of recombinant WNT1 partially reversed the RU-486-dependent inhibition of viability in MCF-7, but not in T-47D cells. In conclusion, we identified WNT1 as a novel mediator of the anti-tumor effects of RU-486 in MCF-7 cells. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available